Ignite Creation Date:
2026-03-26 @ 3:19 PM
Ignite Modification Date:
2026-03-31 @ 3:27 AM
Study NCT ID:
NCT07412860
Status:
RECRUITING
Last Update Posted:
2026-02-17
First Post:
2026-01-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hyaluronic Acid 0.3% (FBV_01) vs Hyaluronic Acid 0.3% in Subjects in the Treatment From Moderate to Severe DED
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2026-03-25'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015352', 'term': 'Dry Eye Syndromes'}], 'ancestors': [{'id': 'D007766', 'term': 'Lacrimal Apparatus Diseases'}, {'id': 'D005128', 'term': 'Eye Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Enrolled partecipants will be randomly assigned in a 1:1 ratio to receive the medical device containing an ancillary medicinal substance and hyaluronic acid 0.3% (FBV\\_01) or hyaluronic acid.'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 74}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2025-03-26', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2026-02', 'completionDateStruct': {'date': '2026-03-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2026-02-09', 'studyFirstSubmitDate': '2026-01-30', 'studyFirstSubmitQcDate': '2026-02-09', 'lastUpdatePostDateStruct': {'date': '2026-02-17', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2026-02-17', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-03-31', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Evaluation IGAS (Investigator Global Assessment of Safety)', 'timeFrame': 'V3 (within 30±4 days after V1)', 'description': 'Evaluation of investigator Global Assessment of Safety (IGAS): using the 4-point scale:1= very good safety, 2 =good safety, 3 = moderate safety and 4 = poor safety. Lower values indicate a better result'}, {'measure': 'Evaluation of records documented in the patient diary', 'timeFrame': 'From V1 (Baseline) to V3 (within 30±4 days after V1)', 'description': 'Evaluation of patient adherence to the medical device during the study through review of the patient diary \\[compliance\\].'}, {'measure': 'Verification of Used and Unused Bottles Through Traceability Labels', 'timeFrame': 'V3 (within 30±4 days after V1 (Baseline))', 'description': 'Counting the number of bottles used, and empty/unused for the patient confirmed by the number of traceability labels detached and kept by the Investigator \\[compliance\\].'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events (TEAEs)', 'timeFrame': 'From V1 (Baseline) to V3 (within 30±4 days after V1)', 'description': 'Evaluation of reported adverse effects/incidents \\[safety\\]'}], 'primaryOutcomes': [{'measure': 'Assessment of SANDE (Symptom Assessment in Dry Eye) questionnaire', 'timeFrame': 'V1 (Baseline), V2 (within 15±2 days after V1), V3 (within 30±4 days after V1)', 'description': 'Change in intensity and frequency of dry eye symptoms assessed by administration of the SANDE (Symptom Assessment in Dry Eye) questionnaire scale (0-100 visual scale). Higher scores mean worse outcome.'}], 'secondaryOutcomes': [{'measure': 'Assessment of BODI (Brief Ocular Discomfort Inventory) questionnaire', 'timeFrame': 'V1 (Baseline), V2 (within 15±2 days after V1), V3 (within 30±4 days after V1)', 'description': 'Assessment of uncomfortable sensation , if present, related to eye drop instillation \\[tolerability\\] by administration of the BODI (Brief Ocular Discomfort Inventory) questionnaire, score ranging from 0 to 10. Higher scores mean worse outcome.'}, {'measure': 'Assessment of Oxford scale', 'timeFrame': 'V1 (Baseline), V2 (within 15±2 days after V1), V3 (within 30±4 days after V1)', 'description': '"Assessment of the severity of keratoconjunctivitis by quantifying corneal and conjunctival staining (fluorescein vital staining) using the Oxford grading scale, ranging from 0 to 5. Higher scores indicate more severe surface damage.'}, {'measure': 'Assessment of TFBUT test (time of tear film rupture with fluorescein)', 'timeFrame': 'V1 (Baseline), V2 (within 15±2 days after V1), V3 (within 30±4 days after V1).', 'description': 'Evaluation of the stability of the tear film and its ability to remain intact on the ocular surface by TFBUT test (time of tear film rupture with fluorescein), expires from 0 to 20 seconds, higher values indicate improvement of the condition.'}, {'measure': 'Assessment of NEIVFQ25 (National Eye Institute Visual Function Questionnaire - 25 items)', 'timeFrame': 'V1 (Baseline), V3 (within 30±4 days after V1)', 'description': 'Measurement of patient-perceived visual function and the impact of eye conditions on daily activities through NEIVFQ25 (National Eye Institute Visual Function Questionnaire - 25 items) . Individual item scores are converted into a composite score ranging from 0 to 100. Higher scores indicate an improvement in the condition'}, {'measure': 'Assessment of IOP (intraocular pressure)', 'timeFrame': 'V1 (Baseline), V2 (within 15±2 days after V1), V3 (within 30±4 days after V1)', 'description': 'Measurement of intraocular pressure (IOP), typically ranging from 10 to 30 mmHg. Lower values indicate an improvement in the condition'}, {'measure': 'Slit-lamp examination (LES)', 'timeFrame': 'V1 (Baseline), V2 (within 15±2 days after V1), V3 (within 30±4 days after V1)', 'description': "Slit-lamp examination (LES) to evaluate anterior segment structures, including the eyelids, conjunctiva, cornea, anterior chamber, iris, and lens. This is a qualitative descriptive assessment, classified as 'normal' or 'abnormal'."}, {'measure': 'Verification of correct medical device use by comparing the number of doses applied with the number of doses expected to be used during the treatment period', 'timeFrame': 'V3 (within 30±4 days after V1)', 'description': 'Recording the number of doses applied and the number of missed doses per day during the treatment period \\[compliance\\].'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['moderate to severe dry eye syndrome', 'dry eye disease'], 'conditions': ['Dry Eye Syndromes', 'Dry Eye Disease (DED)']}, 'descriptionModule': {'briefSummary': 'The goal of this clinical investigation plan is to evaluate the performance, tolerability, safety, and compliance of an ophthalmic solution containing an ancillary medicinal substance and hyaluronic acid 0.3% (FBV\\_01) compared with hyaluronic acid 0.3% alone in adult men and women (≥18 years) with moderate-to-severe dry eye syndrome.\n\nThe main questions it aims to answer are:\n\n* Is the ophthalmic solution containing an ancillary medicinal substance and hyaluronic acid non-inferior in improving the clinical performance outcomes of dry eye compared with hyaluronic acid alone?\n* Is the investigational device safe and well tolerated, with acceptable partecipant compliance over the treatment period?\n\nResearchers will compare the medical device containing an ancillary medicinal substance and hyaluronic acid 0.3% (FBV\\_01) to hyaluronic acid 0.3% alone to see if the combination provides at least equivalent clinical benefit without increased safety issues.\n\nParticipants will be randomly assigned (1:1) to one of two treatment groups in a multicenter, prospective, randomized, open-label, controlled study. Participants will instill 1 drop in both eyes 4 times daily (every 4 ± 1 hours) for 30 ± 4 days and attend study visits for assessments of dry eye signs and symptoms, safety, tolerability, and treatment compliance. The study plans to enroll 74 partecipants, with an enrollment period of about 11 months and a total study duration of approximately 12 months (from first partecipant first visit to last partecipant last visit).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Patients able to provide written Informed Consent, in accordance with good clinical practice and current legislation;\n* Patients (male and female) 18 years of age or older with moderate to severe dry eye syndrome or with dry eye syndrome, even after eye surgery (e.g. refractive surgery or cataract);\n* Moderate to severe dry eye syndrome in one or both eyes in the presence of:\n\n 1. Dry Eye Symptom Assessment Questionnaire (SANDE) \\> 60;\n 2. Tear Film Break-Up Time (TFBUT) \\< 7 seconds. TFBUT value will be recorded as an average of 3 measurements;\n 3. Test di Schirmer \\< 10 mm;\n* Diagnosis of dry eye syndrome for at least 6 months (use or recommendation of use of artificial tears/lubricants for the treatment of dry eye);\n* Patients able to understand the nature and purpose of the study, including possible risks;\n* Patient able to cooperate with the Investigator and meet the requirements of the clinical investigation plan;\n* Patient who, in the opinion of the Investigator, will benefit from this treatment;\n* Patient available for the entire study period.\n\nExclusion Criteria:\n\n* Eye infection or clinically significant inflammation in both eyes (for example: Herpes simplex infections, corneal virus infections, bacterial, viral or fungal conjunctivitis, tuberculosis and mycosis of the eye, purulent and herpetic blepharitis, stye);\n* History or evidence of eyelid abnormalities in either eye;\n* Use of topical cyclosporine, topical corticosteroids, or any other topical medication for the treatment of ocular pathologies in either eye within 7 days of study enrollment;\n* Patients being treated with chronic systemic therapies with analgesic, anti-inflammatory, corticosteroids, or opioids;\n* History of ocular surgery (including laser procedures or refractive surgery) in either eye 7 days prior to enrollment;\n* History or evidence of severe or uncontrolled systemic or autoimmune disease does not allow participation in the study or could impair the results;\n* Patients being treated with drugs and/or medical devices and/or supplements for neuropathic pain (e.g., SNRIs (duloxetine, venlafaxine), pregabalin, gabapentin, TCAs (nortriptyline, amitriptyline));\n* Patient with known or potential allergy or hypersensitivity and/or history of allergic reactions to one of the components of the medical device;\n* Participation in another clinical trial within 30 days prior to the screening visit;\n* History of administration or abuse of drugs, medications, or alcohol;\n* Women of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) will be excluded from participation in the study if they meet any of the following conditions:\n\n 1. are currently pregnant or,\n 2. have a positive urine pregnancy test result at visit 1,\n 3. intend to become pregnant during the study treatment period or,\n 4. are breastfeeding or, unwilling to resort to highly effective birth control measures, such as: hormonal contraceptives oral, implanted, transdermal or injected and/or mechanical barrier methods spermicidal concurrently with a barrier such as a condom or diaphragm or IUD during the entire course of the study and 30 days after the end of the treatment period;\n* Subject unable to follow clinical investigation procedures and follow-up visits;\n* Any other medical condition which, in the opinion of the Investigator, could influence participation in the clinical investigation or compromise its results.'}, 'identificationModule': {'nctId': 'NCT07412860', 'briefTitle': 'Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hyaluronic Acid 0.3% (FBV_01) vs Hyaluronic Acid 0.3% in Subjects in the Treatment From Moderate to Severe DED', 'organization': {'class': 'INDUSTRY', 'fullName': 'FB Vision S.p.A'}, 'officialTitle': 'Interventional, Multi-center, Randomized, Controlled, Open Label Clinical Investigation Between the Topical Administration of a Tear Substitute Containing Ancillary Medicinal Substance and Hyaluronic Acid 0.3% (FBV_01) Versus Hyaluronic Acid 0.3% in Subjects in the Treatment From Moderate to Severe Dry Eye Syndrome', 'orgStudyIdInfo': {'id': 'FBV_01/03/2024'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'FBV_01', 'description': 'Ancillary medicinal substance and hyaluronic acid 0.3%', 'interventionNames': ['Device: FBV_01']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'HYLO-VISION® SafeDrop® Gel', 'description': 'Hyaluronic acid 0.3%', 'interventionNames': ['Device: HYLO-VISION® SafeDrop® Gel']}], 'interventions': [{'name': 'FBV_01', 'type': 'DEVICE', 'description': 'Instill one drop into the conjunctival fornix four times a day.', 'armGroupLabels': ['FBV_01']}, {'name': 'HYLO-VISION® SafeDrop® Gel', 'type': 'DEVICE', 'description': 'Instill one drop into the conjunctival fornix four times a day.', 'armGroupLabels': ['HYLO-VISION® SafeDrop® Gel']}]}, 'contactsLocationsModule': {'locations': [{'zip': '09124', 'city': 'Cagliari', 'state': 'CA', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Giuseppe Giannaccare', 'role': 'CONTACT', 'email': 'giuseppe.giannaccare@unica.it', 'phone': '+39070 51092148'}, {'name': 'Giuseppe Giannaccare', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'S.C. di Oculistica Azienda Ospedaliero-Universitaria di Cagliari Presidio San Giovanni di Dio', 'geoPoint': {'lat': 39.23054, 'lon': 9.11917}}, {'zip': '88100', 'city': 'Catanzaro', 'state': 'CZ', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Vincenzo Scorcia', 'role': 'CONTACT', 'email': 'vscorcia@unicz.it', 'phone': '+390961/883046'}, {'name': 'Vincenzo Scorcia', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'U.O. Oculistica Azienda Ospedaliero-Universitaria Renato Dulbecco', 'geoPoint': {'lat': 38.88247, 'lon': 16.60086}}], 'centralContacts': [{'name': 'Valeria Ipavec', 'role': 'CONTACT', 'email': 'vipavec@fb-vision.it', 'phone': '+39 340 3518447'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'FB Vision S.p.A', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}